[Top Stories] The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus

Browse By

Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the week were mostly disappointing.

Pfizer Inc. (NYSE: PFE) reported disappointing fourth-quarter earnings and Amgen, Inc. (NASDAQ: AMGN) guided 2020 below consensus, while Eli Lilly And Co (NYSE: LLY) managed to outperform expectations.

The week continued to see coronavirus-related spikes, with Cleveland BioLabs, Inc. (NASDAQ: CBLI), NanoViricides, Inc. (NASDAQ: NNVC), Vir Biotechnology, Inc. (NASDAQ: VIR) and Vaccinex, Inc. (NASDAQ: VCNX) among the stocks riding on the momentum.

Acceleron Pharma Inc (NASDAQ: XLRN) was one of the standout gainers of the week, thanks to a positive midstage clinical readout.

The much-anticipated FDA verdict on Aimmune Therapeutics Inc's (NASDAQ: AIMT) peanut allergy drug Palforzia came through in the week, with the regulatory agency greenlighting the drug.

Related Link: 7 Blockbuster Drugs Expected To Be Launched In 2020

Turning ahead to the unfolding week, the following are key catalysts that could create a ripple in the biotech space.


  • 2nd International Scientific & Clinical Congress on Spinal Muscular Atrophy: Feb. 5-7 in Paris, France
  • The European Association for Hemophilia and Allied Disorders, or EAHAD, 2020 Congress: Feb. 5-7 in Hague, Netherlands
  • ASCO-SITC Clinical Immuno-Oncology Symposium: Feb. 6-8 in Orlando, Florida
  • Angiogenesis, Exudation, and Degeneration 2020: Feb. 8 in Miami, Florida

Clinical Readouts

Forty Seven Inc …

Full story available on Benzinga.com

Source Benzinga

Disclaimer: All posts made on this website are provided for information purposes only. None of the information here is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, Company, or fund. Before making an investment decision, you should seek the advice of a qualified and registered securities professional. The author is not paid to share this information. Cannabis Investment Group is not paid to share this information and has no business relationship other than shareholder with any company whose stock is mentioned in this article.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.